{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-092520","form_type":"8-K","ticker":"CLYM","cik":"0001768446","company_name":"Climb Bio, Inc.","filed_at":"2026-03-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.114998+00:00","generated_at":"2026-05-15T19:47:30.370528+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Climb Bio reports Q4/FY2025 results; cash $160.7M; pipeline trials on track with data in 2026","bullets":["Cash, cash equivalents, and marketable securities $160.7M as of Dec 31, 2025; expected runway into 2028.","FY2025 R&D expense $46.7M vs $14.3M in FY2024; G&A expense $21.2M vs $16.0M.","Budoprutug SC formulation Phase 1 dosing completed; data expected H1 2026.","Budoprutug pMN, ITP, SLE trials ongoing; initial efficacy data expected H2 2026.","CLYM116 Phase 1 healthy volunteer study enrollment ongoing; initial data expected mid-2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-092520","json":"https://secwatch.observer/filing/0001193125-26-092520.json","markdown":"https://secwatch.observer/filing/0001193125-26-092520.md","text":"https://secwatch.observer/filing/0001193125-26-092520.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1768446/000119312526092520/0001193125-26-092520-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1768446/000119312526092520/clym-20260305.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T19:47:30.370528+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"928ef95a96a716945f4797b320875b5a445508b4","claim":"Climb Bio, Inc. reported financial results for fourth quarter and full year ended December 31, 2025.","evidence_excerpt":"Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided business updates.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1768446/000119312526092520/0001193125-26-092520-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and full year ended December 31, 2025"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}